Newcastle University

Roles and Responsibilities

Professor of Paediatric Oncology, Newcastle University

Honorary Consultant in Paediatric & Adolescent Oncology, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust

Qualifications

BSc (Hons), Manchester University, 1988
MB ChB (Hons), Manchester University, 1991
Member of the Royal College of Physicians/Paediatrics and Child Health, 1994
PhD, Newcastle University, 2002
Fellow of the the Royal College of Paediatrics & Child Health, 2005

Previous Positions

Senior Lecturer & Honorary Consultant in Paediatric & Adolescent Oncology, 2004-2011 

Lecturer & Honorary Registrar in Paediatric Oncology, 2002-2004 

Department of Health Clinician Scientist Fellowship, Newcastle University, 2002-2008

Specialist Registrar in Paediatrics, Newcastle and North Tyneside Hospitals,1999-2002
Research Registrar in Paediatric Oncology, Newcastle University, 1996-1999
LRF Fellow in Paediatric Oncology, Newcastle Hospitals 1995-1996
SHO and Senior Resident in Paediatrics, John Radcliffe Hospital, Oxford and Duke University Hospital, North Carolina, USA 1993-1995
SHO and PRHO in Medicine and Surgery, Manchester Hospitals, 1991-1992

Memberships

Royal College of Paediatrics & Child Health
United Kingdom Children's Cancer and leukaemia Group
British Association for Cancer Research
American Association for Cancer Research
British Medical Association
National Cancer Research Institute (NCRI) Children's Cancer & Leukaemia Clinical Studies Group, Neuroblastoma Subgroup

Chair of UK Children's Cancer & Leukaemia Group Neuroblastoma Special Interest Group

Medical Trustee of Neuroblastoma Society

Honours and Awards

MB ChB with Honours, Distinction-Psychiatry, Honours- Paediatrics, Anatomy, Physiology, Biochemistry, Pharmacology, Public Health & Epidemiology
Kessel Psychiatry Prize, Manchester,1991
Liversege Memorial Prize for Elective Report,Boston Children's Hospital and Dana Farber Cancer Insitute,1991
Henri-Mousalli Case Presentation Award, Manchester 1992,
Young Investigator Award, Advances in Neuroblastoma Research, Bath, 1998,
Sylvia Lawler Prize, Royal Society of Medicine,London, 2001,
SPARKS Young Investigator Award, Royal College of Paediatrics & Child Health, York, 2003

Languages

English

Research Interests

Childhood neuroblastoma - biological, translational and clinical

Postgraduate Supervision

5 PhD students, 1 Staff PhD

6 MRes students

Funding

MRC Intercalated studentship, 1988
North of England Children's Cancer Research Fund, Clinical Fellowship, 1996-1999
Department of Health Clinician Scientist Award, 2002-2008
Cancer Research UK, PhD studentship,2003-2007
Cancer Research UK, Continuation of a national neuroblastoma molecular diagnostic service, 2004-2006
Cancer Research UK, PhD studentship,2005-2009
Cancer Research UK, Drug Development Award, 2005-2007
Neuroblastoma Society Project Grant, 2005-2008
Department of Health, Continuation of a national neuroblastoma molecular diagnostic service, 2006-2008
Cancer Research UK, PhD studentship, 2007-2011
Newcastle Healthcare Charity, 2007-2008
Newcastle Healthcare Charity, 2008-2009

Neuroblastoma Society, Neuroblastoma Reference Centre Service

Cancer Research UK, PhD studentship, 2010-2013
Cancer Research UK, Small Grant, 2010-2011

Neuroblastoma Society, 2010-2012

JGW Paterson Foundation, 2011-2012 

Patents

None

• Gamble LD, Kees UR, Tweddle DA, Lunec J. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene 2012, 31, 752-763.
• Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Research 2010, 70(4), 1377-1388.
• Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF. A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clinical Cancer Research 2011, 17(4), 792-804.
• Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NV, Boos J, Kohler G, Leuschner I, Pearson ADJ, Lunec J, Tweddle DA. High frequency of p53/MDM2/p14^ARF pathway abnormalities in relapsed neuroblastoma. Clinical Cancer Research 2010, 16(4), 1108-1118.
• Bomken S, Davies B, Chong L, Cole M, Wood KM, McDermott M, Tweddle DA. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival. Pediatric Hematology & Oncology 2011, 28(2), 106-114.
• Bell E, Chen LD, Liu T, Marshall GM, Lunec J, Tweddle DA. MYCN oncoprotein targets and their therapeutic potential. Cancer Letters 2010. ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND: ELSEVIER IRELAND LTD, 293(2), 144-157.
• Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British Journal of Cancer 2010,103 10 1588-1596.
• Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC. Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma. Clinical Cancer Research 2009, 15(4), 1241-1249.
• Bell, E., Lunec, J., Tweddle, D. Cell cycle regulation targets of MYCN identified by gene expression microarrays. Cell Cycle 2007,6 10 1249-1256.
• Chen L, Malcolm AJ, Wood K, Cole M, Variend S, Cullinane C, Pearson ADJ, Lunec J, Tweddle DA. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 2007,6 21 2685-2696.
• Carr J, Bell E, Pearson ADJ, Kees U, Beris H, Lunec J, Tweddle DA. Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse. Cancer Research 2006, 66(4), 2138-2145.
• Tweddle, D.A., Pearson, A.D.J., Haber, M., Norris, M., Xue, C., Flemming, C., Lunec, J. The p53 pathway and its inactivation in neuroblastoma. Cancer Letters 2003, 197(1-2), 93-98.
• Tweddle, D. A., Malcolm, A. J., Bown, N. P., Pearson, A. D. J., Lunec, J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Research 2001, 61(1), 8-13.
• Tweddle, D. A., Malcolm, A. J., Cole, M., Pearson, A. D. J., Lunec, J. p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells. American Journal of Pathology 2001, 158(6), 2067-2077.
• Carr-Wilkinson J, Griffiths R, Elston R, Goranov B, Redfern CPF, Gamble LD, Lunec J, Tweddle DA. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Cell Cycle 2011, 10(21), 3778-3787.
• Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Benard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Canete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, de Bernardi B, di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). British Journal of Cancer 2011, 105(12), 1940-1948.